RESEARCH MONOGRAPH · KDC-MN-191

Vortioxetine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

74/100

The SSRI-adjacent antidepressant with the most interesting cognitive signal nobody markets correctly

Vortioxetine is genuinely one of the more pharmacologically novel approved antidepressants of the last fifteen years, and the cognitive endpoint data is what makes it actually interesting. Mechanism is messy in the productive way: SERT inhibition like an SSRI, but also 5-HT3 antagonism (the ondansetron mechanism, useful for nausea profile and possibly the cognitive piece), 5-HT7 antagonism, 5-HT1A agonism, 5-HT1B partial agonism, and 5-HT1D antagonism. The Lundbeck program called it a multimodal serotonergic agent and the receptor pharmacology actually justifies the term, unlike a lot of pharma marketing.

What's genuinely interesting is the cognitive performance signal. The FOCUS and CONNECT trials showed effects on digit symbol substitution and verbal learning that were independent of mood improvement, which is unusual for the antidepressant class. SSRIs generally either dont affect cognition or modestly impair it. Vortioxetine has reasonable evidence for the opposite, probably mediated by 5-HT3 antagonism and downstream effects on hippocampal glutamatergic transmission. Thats a research finding worth taking seriously.

The clinical reality is less exciting. Antidepressant efficacy in head-to-head trials against venlafaxine and SSRIs is roughly equivalent at best, the discontinuation profile is favorable (long half-life around 66 hours means cleaner taper), and the sexual side effect rate appears genuinely lower than SSRIs in the comparative data, though still not zero. Nausea is the dominant tolerability issue and usually fades in 1-2 weeks.

What we don't like is the price. Brand-name Trintellix / Brintellix is absurdly expensive in the US relative to generic SSRIs that work nearly as well for most depression endpoints. The cost-benefit only makes sense if you're specifically chasing the cognitive endpoint or have failed multiple SSRIs on side effects.

Sourcing for research-use material is straightforward, the molecule has been characterized to death and the patent landscape is mature enough that reference standards are widely available. Honestly underused as a tool compound for studying multi-target serotonergic pharmacology, and the cognitive endpoint data deserves more attention than the prescribing community gives it.

Evidence: 78
Mechanism: 82
Reliability: 72
Safety: 80
Sourcing: 80
Value: 55
Signal: 70
Staying power: 72

Plain-language summary Intrigue 75 / 100

Vortioxetine, sold as Trintellix, is a multimodal antidepressant approved by the FDA in 2013. It combines SERT inhibition with multiple serotonin receptor effects (5-HT1A agonism, 5-HT3 antagonism, and others), reportedly with cognitive benefits beyond typical SSRIs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Multimodal serotonergic antidepressant

A multimodal serotonergic antidepressant (Trintellix) FDA-approved 2013 with documented cognitive benefits in addition to mood effects.

Abstract

Vortioxetine (Trintellix, Brintellix; CAS 508233-74-7; molecular formula C18H22N2S; molecular weight 298.45) is a multimodal serotonergic antidepressant developed by Lundbeck and Takeda and approved by the FDA in 2013 for major depressive disorder. Mechanism includes serotonin reuptake inhibition (SERT), 5-HT3 antagonism, 5-HT7 antagonism, 5-HT1A agonism, 5-HT1B partial agonism, and 5-HT1D antagonism. The combination produces a clinical profile with antidepressant efficacy plus documented improvements in cognitive function (executive function, processing speed) that are distinct from typical SSRI cognitive profiles. Reported research dose ranges in the literature are described in the source publications. Generally well tolerated.

Mechanism of action

Multimodal serotonergic: SERT inhibition, 5-HT3/5-HT7/5-HT1D antagonism, 5-HT1A agonism, 5-HT1B partial agonism.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Mc Intyre RS, et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder. Int J Neuropsychopharmacol 2014.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-191

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Vortioxetine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs